当前位置:药药网 / 数据中心 / 生物制药海外临床研究状况
Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load
标题(英文)
Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load
条件
Biochemically Recurrent Prostate Carcinoma|Prostate Adenocarcinoma
干预
Biological: Durvalumab|Drug: Olaparib|Other: Quality-of-Life Assessment|Other: Questionnaire Administration